Rahul Modi, Founder and CEO, Envision

07/13/19 • 33 min

Rahul is a health-tech optimist, serial entrepreneur, and biomedical engineer. His affinity for (sensible) innovation is only challenged by his predilection for building customer-obsessed companies. He's a dream-catcher with unbridled curiosity and a strong operator who enjoys delivering value in large markets ripe for change. Humble beginnings not only keep him anchored, but shape the distinct perspective he brings to the table.

More recently, Rahul was the director and founding member of EyeNetra – an MIT Media Lab spinout recognized worldwide for pioneering smartphone-powered refractions to serve the 4.5B individuals in need of vision correction. It's commonly cited that more than half of said populace remains uncorrected to this day. At EyeNetra, he contributed to the development of 4 products from inception, honed their go-to-market strategy, and architected a successful platform for global growth. Thousands of units were both sold and shipped to eye care professionals in over 90 countries within a span of 36 months. By maintaining lean operations, the company eventually became cash flow positive – a rarity at the intersection of hardware, software, and healthcare in an overcapitalized climate. The team also explored a first of its kind model for teleoptometry and spent years in deep R&D, clinical trials, regulatory approvals, and manufacturing prior to commercialization. Confronted along the way were countless moments fraught with uncertainty including an abundance of failures. To-date, this technology suite has facilitated 5 million refractions and a quarter-million connected exams (and counting). It would be remiss not to mention the smiles conjured of millions more from the friends, families, and caretakers of patients.

Previous Episode

Jonathan Rourke, Co-Founder & CEO, MitraSpan

Jonathan (Jon) is co-founder & CEO at MitraSpan —a medical device development company that is exploring minimally invasive mitral valve repair techniques for treating type IIIb functional mitral regurgitation in heart failure patients.

Jon's career in medical devices and cardiology began in 1991 in the ultrasound imaging business at Hewlett-Packard Medical Products (now owned by Philips). He worked on engineering challenges related to manufacturing high-frequency ultrasound transducers for both TTE and TEE devices. In 1995, he led the IVUS catheter program, a joint venture first with Boston Scientific and later Guidant. This business was later spun out to Volcano and then recently acquired back by Philips. In 1999, Jon moved to the venture-backed startup world where he has remained for now 20 years first as VP of R&D at Endotex where he focused on the development of a carotid stent. He led this program through successful feasibility studies and pivotal study launch. Following that and FDA-PMA approval, Endotex was acquired by BSX. In 2001, Jon joined TransMedics as VP of R&D and lead development efforts through the successful completion of the first full venture round. Transmedics recently filed for an IPO and is a pioneering company focused on the normothermic, sanguineous, functional preservation of organs for transplantation.

Since 2002, Jon has led a succession of development and clinical trial efforts in the structural heart and mitral repair fields. First, at Viacor he served as both VP of R&D and CEO; and later at Harpoon, he helped arrange for the spinout of IP and the securement of initial program funding. Now, at MitraSpan he continues to innovate on potential breakthrough structural techniques.

Next Episode

John Hendrick, President, Safeco

Mr. Hendrick has over three decades of executive experience, building both early-stage medical device companies as well as large divisions in medical device corporations. Currently, Mr. Hendrick is president of Safeco a medical device consulting company. Previously, he was CEO of Mynosys Cellular Devices —an ophthalmic company. Prior to that, he was CEO at NeoVista Inc. —a company in the field of age-related macular degeneration. Prior to that, he created the medical division at Sanmina-Sci. Mr. Hendrick has been through a successful IPO of VidaMed; which led eventually to Medtronic acquiring the company. Prior to VidaMed, Mr. Hendrick held executive positions at Allergan Medical Optics, Baxter, and American Hospital Supply along with several board positions.